The sentence in the case against the German chemical group Bayer was significantly lowered by a judge in the US state of Pennsylvania, reducing the amount of compensation from $2.25 billion to $400 million, the Dutch portal Nieuwe Oogst reported on June 6. .
This is the compensation that Bayer must pay to a man who claims to have developed cancer from the use of the herbicide Roundup, whose main active ingredient is the pesticide glyphosate. Bayer continues to challenge the compensation order and argues that errors were made in the process.
According to chemistry, there are various studies that show that the glyphosate-based product does not pose any risk to public health. Additionally, Bayer believes that the US legal system should offer greater protection to companies whose products have been tested and approved by federal agencies. Last year, the company was forced to suspend sales of Roundup to the private market in the United States.
Meanwhile, twenty lawsuits have already been filed for the use of the herbicide, in which people ask for compensation because they were diagnosed with some type of cancer. Bayer has won 14 of those cases, but the group also faces thousands of lawsuits that judges must rule on.
Roundup has been part of Bayer’s product line since 2018, when the company acquired Monsanto. Bayer paid approximately $63 billion for the acquisition.
Source: Rossa Primavera
I am Michael Melvin, an experienced news writer with a passion for uncovering stories and bringing them to the public. I have been working in the news industry for over five years now, and my work has been published on multiple websites. As an author at 24 News Reporters, I cover world section of current events stories that are both informative and captivating to read.